Antiviral therapy with nucleoside analogs demonstrated an improvement in survival for sorafenib-treated patients with hepatitis B virus-related hepatocellular carcinoma.
Antiviral therapy with nucleoside analogs demonstrated an improvement in survival for sorafenib-treated patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study published in theJournal of Gastroenterology and Hepatology.
Various phase IV studies are assessing the influence of antiviral therapy on long-term outcomes for patients with HBV infections and related HCC.
"Antiviral therapy with nucleoside analogs improved overall survival of HBV-related HCC patients treated with sorafenib, especially in patients with BCLC stage C disease and higher HBV-DNA level," the authors of the study wrote.
The retrospective analysis looked at 151 patients with HBV-related HCC following prior treatment with sorafenib at the Sun Yat-sen University Cancer Center, in China. Overall, 88 patients received antiviral therapy while 63 did not.
Patients in the nucleoside analog group experienced a significant reduction in the risk of death compared with the non-antiviral group. The median overall survival in treated patients was 16.5 months compared with 13.1 months (HR = 0.67; 95% CI, 0.56-0.98;P= .04).
A subgroup analysis revealed that patients with BCLC stage C and those with higher pre-sorafenib HBV-DNA levels experienced a greater survival advantage.
"Antiviral therapy with nucleoside analogs was one of the independent prognostic factors for OS of HBV-related HCC patients treated with sorafenib," the authors wrote.
A previous study published inJAMAdemonstrated similar findings. In this analysis, patients treated with nucleoside analogs experienced a lower HCC recurrence rate at 6 years compared with untreated patients following liver resection.
In this Taiwanese study, the 6-year recurrence rate in patients with HBV-related HCC with antiviral therapy was 45.6% versus 54.6% without. Mortality rates in the treatment arm were 29% versus 42.4% in untreated patients.
"The treated cohort had a higher prevalence of liver cirrhosis when compared with the untreated cohort, but lower risk of HCC recurrence," the authors noted.
While a majority of adult patients infected with hepatitis B recover, 90% of infants and up to 50% of young children infected with the virus develop chronic infections. The annual incidence of HCC in HBV carriers is 0.5% to 1%.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
2 Commerce Drive
Cranbury, NJ 08512